TABLE 4.
Baseline Medication Use and Treatment Escalation Stratified by Treatment Algorithm and Disease Location
| Isolated Colonic CD | Ileal-Dominant CD | ||||
|---|---|---|---|---|---|
| CM | ECI | CM | ECI | ||
| Proportion of patients on different medications at each time point | |||||
| Steroids | |||||
| Month 0 | 29/178 (16.3%) | 47/257 (18.3%) | 124/717 (17.3%) | 157/817 (19.2%) | |
| Month 12 | 17/152 (11.2%) | 21/217 (9.7%) | 72/628 (11.5%) | 70/679 (10.3%) | |
| Month 24 | 13/123 (10.6%) | 10/171 (5.9%) | 74/550 (13.5%) | 42/556 (7.6%) | |
| Antimetabolite monotherapy | |||||
| Month 0 | 78/178 (43.8%) | 110/257 (42.8%) | 287/717 (40.0%) | 376/817 (46.0%) | |
| Month 12 | 74/152 (48.7%) | 106/217 (48.9%) | 261/628 (41.6%) | 353/679 (52.0%) | |
| Month 24 | 64/123 (52.0%) | 85/171 (49.7%) | 235/550 (42.7%) | 286/556 (51.4%) | |
| TNF-antagonist monotherapy | |||||
| Month 0 | 66/178 (37.1%) | 80/257 (31.1%) | 246/717 (34.3%) | 261/817 (32.0%) | |
| Month 12 | 68/152 (44.7%) | 105/217 (48.4%) | 248/628 (39.5%) | 285/679 (42.0%) | |
| Month 24 | 58/123 (47.2%) | 82/171 (48.0%) | 218/550 (39.6%) | 245/556 (44.1%) | |
| Combination antimetabolite and TNF antagonist | |||||
| Month 0 | 26/178 (14.6%) | 25/257 (9.7%) | 90/717 (12.6%) | 103/817 (12.6%) | |
| Month 12 | 33/152 (21.7%) | 52/217 (24.0%) | 96/628 (15.3%) | 142/679 (20.9%) | |
| Month 24 | 30/123 (24.4%) | 44/171 (25.7%) | 85/550 (15.5%) | 114/556 (20.5%) | |
| Cumulative rates of treatment with different medications | |||||
| Steroids | |||||
| Month 12 | 14.0% | 11.9% | 14.3% | 15.2% | |
| Month 24 | 23.0% | 18.8% | 20.8% | 21.6% | |
| Antimetabolite monotherapy | |||||
| Month 12 | 8.8% | 20.0% | 10.1% | 20.2% | |
| Month 24 | 13.0% | 23.9% | 16.1% | 27.7% | |
| TNF-antagonist monotherapy | |||||
| Month 12 | 15.7% | 22.1% | 12.6% | 21.3% | |
| Month 24 | 20.6% | 26.9% | 16.8% | 27.4% | |
| Combination antimetabolite and TNF antagonist | |||||
| Month 12 | 9.3% | 19.0% | 5.8% | 13.7% | |
| Month 24 | 12.9% | 21.4% | 8.9% | 19.0% |